<div id="readability-page-1"><p>Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) CEO David James Lennon sold 5,690 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $2.35, for a total value of $13,371.50. Following the sale, the chief executive officer now owns 33,429 shares of the company's stock, valued at approximately $78,558.15. This trade represents a 14.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.</p><div><p><span></span><span>Get <strong>Aadi Bioscience</strong> alerts:</span></p></div><h2>Aadi Bioscience Stock Performance</h2><p>Shares of AADI traded down $0.26 during trading hours on Monday, hitting $2.30. 217,778 shares of the company were exchanged, compared to its average volume of 174,224. The company has a market cap of $56.80 million, a PE ratio of -1.01 and a beta of 0.64. The firm's 50 day moving average is $2.95 and its 200-day moving average is $2.37. Aadi Bioscience, Inc. has a 52 week low of $1.21 and a 52 week high of $3.81. </p><h2>Hedge Funds Weigh In On Aadi Bioscience</h2><p>Several large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of  Aadi Bioscience during the 3rd quarter worth about $32,000.  Two Sigma Advisers LP lifted its position in shares of  Aadi Bioscience by 95.2% during the 4th quarter. Two Sigma Advisers LP now owns 61,686 shares of the company's stock worth $195,000 after purchasing an additional 30,086 shares during the last quarter.  Two Sigma Investments LP lifted its position in shares of  Aadi Bioscience by 305.2% during the 4th quarter. Two Sigma Investments LP now owns 68,555 shares of the company's stock worth $216,000 after purchasing an additional 51,638 shares during the last quarter.  Northern Trust Corp lifted its position in shares of  Aadi Bioscience by 33.1% during the 4th quarter. Northern Trust Corp now owns 91,151 shares of the company's stock worth $288,000 after purchasing an additional 22,677 shares during the last quarter.  Finally, Bridgeway Capital Management LLC lifted its position in shares of  Aadi Bioscience by 23.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock worth $364,000 after purchasing an additional 22,100 shares during the last quarter. Institutional investors and hedge funds own  52.08% of the company's stock. </p><h2>Aadi Bioscience Company Profile</h2> (Get Free Report)<p>Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Aadi Bioscience</li><li>3 Small Caps With Big Return Potential</li><li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aadi Bioscience Right Now?</h2><p>Before you consider Aadi Bioscience, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.</p><p>While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AADI

WHWK

<p>Aadi Bioscience, Inc. CEO David James Lennon sold 5,690 shares of stock at an average price of $2.35, totaling $13,371.50. Post-sale, he holds 33,429 shares valued at approximately $78,558.15, reflecting a 14.55% decrease in ownership. The transaction was filed with the SEC. Aadi's stock traded down to $2.30, with a market cap of $56.80 million. Institutional investors own 52.08% of the company, which focuses on precision therapies for genetically defined cancers.</p>

Insider Selling: Aadi Bioscience, Inc. (NASDAQ:AADI) CEO Sells 5,690 Shares of Stock